Suche

Arexvy · 4.8 · In a phase 3 open-label study (RSV OA=ADJ-025) that included participants 18 through 49 years of age (N = 1 02

Arexvy · 4.8 · In a phase 3 placebo-controlled study (RSV OA=ADJ-006), participants 60 years of age and older received either

Arexvy · 4.8 · In a phase 3 placebo-controlled study (RSV OA=ADJ-018) that included participants 50 through 59 years of age (

Beyonttra · 4.8 · The safety data reflect exposure of 421 participants with ATTR-CM to acoramidis 712 mg (as two tablets of 356

Bosulif · 4.8 · Hepatobiliary disorders Of the 55 participants, the incidence based on laboratory data of ALT and AST increase

Comirnaty · 4.8 · 115 8.5 months after receiving Dose 3. Participants who received a booster (fourth dose) of Comirnaty Original

Evaluating the impact of antioxidant enzymes on cardiometabolic health markers among methamphetamine users compared with healthy participants

pubmed · 42436629

Psychological traits of extreme sport participants: a scoping review

pubmed · 39380030

Association of high-intensity evening light exposure with risk of incident age-related macular degeneration, cataract, and glaucoma: a prospective cohort study of 82,826 participants

pubmed · 42230852

Association of increased depressive symptoms and lung health in participants with pre-COPD: A population-based study

pubmed · 42484451

Humoral immune response to polyvalent pneumococcal vaccine in healthy participants receiving efgartigimod: a randomized, open-label, placebo-controlled, parallel-group phase 1 trial

pubmed · 42183242